Abstract
Chronic obstructive pulmonary disease (COPD) is a progressive, inflammatory condition, involving airways and lung parenchyma. The disease leads to airflow limitation, and pulmonary hyperinflation, resulting in dyspnea, decreased exercise tolerance, and impaired quality of life. COPD pharmacotherapy guidelines are based on a combination of long-acting beta2-agonists (LABA), long-acting antimuscarinic agents (LAMA) and methyloxantins. Recently, indacaterol, ultralong acting beta2-agonist, has been introduced. The aim of our study was to assess the impact of indacaterol add-on therapy on lung function, exercise tolerance and quality of life of COPD patients. Thirty four COPD patients, receiving stable bronchodilator therapy were randomly allocated into two arms of add-on treatment (1:1 – indacaterol:placebo) for 3 months. Indacaterol replaced LABA in all patients receiving LABA. Spirometry, lung volumes, DLCO, St George’s Respiratory Questionnaire (SGRQ) and 6 min Walk Distance (6MWD) were performed before and after therapy. We found that in the indacaterol group FEV1 did not changed significantly. However, there were significant improvements in ERV, 6MWD, and 6MWD-related dyspnea score. We also found that the degree of desaturation before and after 6MWD, and fatigue levels significantly improved in the indacaterol group. The patients’ quality of life also changed favorably in the indacaterol treatment arm. We conclude that the add-on therapy with indacaterol exerts positive effects in COPD patients.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bailey, S. P., Brown, L., & Bailey, E. K. (2008). Lack of relationship between functional and perceived quality of life outcomes following pulmonary rehabilitation. Cardiopulmonary Physical Therapy Journal, 19(1), 3–10.
Beeh, K. M., Wagner, F., Khindri, S., & Drollmann, A. F. (2011). Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD, 8, 340–345.
Camargo, L. A., & Pereira, C. A. (2010). Dyspnea in COPD: Beyond the modified Medical Research Council scale. Jornal Brasileiro de Pneumologia, 36(5), 571–578.
Cazzola, M., Santangelo, G., Piccolo, A., Salzillo, A., Matera, M. G., D’Amato, G., & Rossi, F. (1994). Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulmonary Pharmacology, 7(2), 103–107.
Cazzola, M., Matera, M. G., & Lotvall, J. (2005). Ultra long-acting beta2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opinion on Investigational Drugs, 14(7), 775–783.
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., de Montes, O. M., Mendez, R. A., Pinto, P. V., & Cabral, H. J. (2004). The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. The New England Journal of Medicine, 350(10), 1005–1012.
Eisner, M. D., Iribarren, C., Yelin, E. H., Sidney, S., Katz, P. P., Ackerson, L., Lathon, P., Tolstykh, I., Omachi, T., Byl, N., & Blanc, P. D. (2008). Pulmonary function and the risk of functional limitation in chronic obstructive pulmonary disease. American Journal of Epidemiology, 167(9), 1090–1101.
Ford, E. S., Mannino, D. M., Zhao, G., Li, C., & Croft, J. B. (2011). Changes in mortality among United States adults with chronic obstructive pulmonary disease in two national cohorts recruited during 1971 through 1975 and 1988 through 1994. Chest, 141, 101–110.
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991). The St George’s respiratory questionnaire. Respiratory Medicine, 85(Suppl B), 25–31.
Jones, P. W., Barnes, N., Vogelmeier, C., Lawrence, D., & Kramer, B. (2011). Efficacy of indacaterol in the treatment of patients with COPD. Primary Care Respiratory Journal, 20(4), 380–388.
Leckie, M. J., Bryan, S. A., Hansel, T. T., & Barnes, P. J. (2000). Novel therapy for COPD. Expert Opinion on Investigational Drugs, 9(1), 3–23.
Macklem, P. T. (2010). Therapeutic implications of the pathophysiology of COPD. European Respiratory Journal, 35(3), 676–680.
Maesen, F. P., Smeets, J. J., Costongs, M. A., Wald, F. D., & Cornelissen, P. J. (1993). Ba 679 Br, a new long-acting antimuscarinic bronchodilator: A pilot dose-escalation study in COPD. European Respiratory Journal, 6(7), 1031–1036.
Mannino, D. M., & Buist, A. S. (2007). Global burden of COPD: Risk factors, prevalence, and future trends. Lancet, 370(9589), 765–773.
Moy, M. L., Reilly, J. J., Ries, A. L., Mosenifar, Z., Kaplan, R. M., Lew, R., & Garshick, E. (2009). Multivariate models of determinants of health-related quality of life in severe chronic obstructive pulmonary disease. Journal of Rehabilitation Research and Development, 46(5), 643–654.
O’Donnell, D. E., Casaburi, R., Vincken, W., Puente-Maestu, L., Swales, J., Lawrence, D., & Kramer, B. (2011). Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respiratory Medicine, 105(7), 1030–1036.
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., & Zielinski, J. (2007). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. American Journal of Respiratory and Critical Care Medicine, 176(6), 532–555.
Sciurba, F., Criner, G. J., Lee, S. M., Mohsenifar, Z., Shade, D., Slivka, W., & Wise, R. A. (2003). Six-minute walk distance in chronic obstructive pulmonary disease: Reproducibility and effect of walking course layout and length. American Journal of Respiratory and Critical Care Medicine, 167(11), 1522–1527.
Tashkin, D. P., & Fabbri, L. M. (2010). Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: Current and future agents. Respiratory Research, 11, 149.
Westwood, M., Bourbeau, J., Jones, P. W., Cerulli, A., Capkun-Niggli, G., & Worthy, G. (2011). Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: A systematic review. Respiratory Research, 12, 40.
Conflicts of interest: The authors declare no conflicts of interest in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this paper
Cite this paper
Mroz, R.M., Minarowski, L., Chyczewska, E. (2013). Indacaterol Add-On Therapy Improves Lung Function, Exercise Capacity and Life Quality of COPD Patients. In: Pokorski, M. (eds) Respiratory Regulation - The Molecular Approach. Advances in Experimental Medicine and Biology, vol 756. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-4549-0_4
Download citation
DOI: https://doi.org/10.1007/978-94-007-4549-0_4
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-4548-3
Online ISBN: 978-94-007-4549-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)